ImmunAdd today announced an update on the progress of its patent portfolio. Effective this year, the company has adopted a new disclosure policy under which it no longer announces the grant or filing status of individual patents on a case-by-case basis, and instead provides periodic, consolidated updates on the overall progress of its portfolio.

As of January 22, 2026, ImmunAdd has filed a cumulative total of 31 patent applications, of which 14 have been granted, with additional PCT applications expected to enter national-phase examination in due course.

ImmunAdd’s patents relate primarily to technologies and products arising from the company’s core adjuvant development. ImmunAdd will continue to strengthen its global patent portfolio, establishing a solid intellectual-property foundation for the research, development, and commercialization of its next-generation vaccine adjuvants and related products.